Skip to main content

DARE

Stock
Health Care
Biotechnology

Performance overview

DARE Price
Price Chart

Forward-looking statistics

Beta
0.96
Risk
80.50%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

daré bioscience (nasdaq: dare) is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s reproductive health. we are driven by a mission to identify, develop and bring to market a diverse portfolio of novel therapies that expand treatment options, improve outcomes and facilitate convenience for women. we are initially focused on the areas of contraception, vaginal health and fertility. our lead product candidate, ovaprene, is a non-hormonal, monthly contraceptive ring that is currently in clinical studies.

Company info

SectorHealth Care
IndustryBiotechnology
Employees26
Market cap$52.6M

Fundamentals

Enterprise value$14.4M
Revenue$25.9K
Revenue per employee
Profit margin0.00%
Debt to equity-0.37

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.17
Dividend per share
Revenue per share$0.00
Avg trading volume (30 day)$83K
Avg trading volume (10 day)$107K
Put-call ratio

Macro factor sensitivity

Growth+2.3
Credit+4.0
Liquidity-1.8
Inflation-0.4
Commodities+0.7
Interest Rates-1.2

Valuation

Dividend yield0.00%
PEG Ratio-1.76
Price to sales819.83
P/E Ratio-1.76
Enterprise Value to Revenue555.60
Price to book-2.20

Upcoming events

Next earnings dayMay 14, 2025
Next dividend day
Ex. dividend day

News

Crude Oil Moves Lower; Daré Bioscience Shares Jump

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 0.4% on Monday.

Benzinga (July 14, 2025)
Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates

Dare Bioscience, Inc. (DARE) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $0.84 per share a year ago.

Zacks Investment Research (May 13, 2025)
This overlooked corner of women's health could be a $350 billion market opportunity

Menopause is among the female health conditions with the highest unmet need and has 'enormous potential for innovative treatments,' according to McKinsey.

CNBC (March 15, 2024)
Organon Inks Licensing Pact For Daré Bioscience's Bacterial Vaginosis Treatment

Organon & Co (NYSE: OGN) will license global rights to Daré Bioscience Inc's (NASDAQ: DARE) Xaciato (clindamycin phosphate vaginal gel, 2%).  Xaciato is an FDA-approved medication for treating bacterial vaginosis (BV) in females 12 years of age and.

Benzinga (March 31, 2022)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free